Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioAlliance Pharma Completes Patient Enrolment Ahead of Schedule for Its Pivotal Phase III Clinical Trial of Loramyc® in The USA for the Treatment of

Abstract:
Regulatory News:

BioAlliance Pharma SA (Paris:BIO), today announced that it had successfully completed patient enrolment in the pivotal phase III clinical trial performed with a view to registering Loramyc® in the US, for the treatment of oropharyngeal candidiasis. With 540 patients enrolled by 40 specialist clinical centers in the USA, Canada and South Africa, the company has achieved its target ahead of schedule. The trial results are expected in the first half of 2008. The company plans to file a market authorization application in the second half of next year, subject to the FDA's regulatory requirements.

BioAlliance Pharma Completes Patient Enrolment Ahead of Schedule for Its Pivotal Phase III Clinical Trial of Loramyc® in The USA for the Treatment of

PARIS, France | Posted on November 16th, 2007

"Our development team has proved its effectiveness in successfully completing the enrolment process", commented Dominique Costantini, BioAlliance Pharma's President and CEO. "This milestone is a significant one in our alliance with Par Pharmaceutical, which will commercialize our product in the US - the world's leading market for oropharyngeal candidiasis treatments," she added.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues and has launched its first portfolio product (Loramyc®) in France. Three innovative products are currently in phase III clinical development: two based on the Lauriad® muco-adhesive technology, which enables targeted release at the disease site (Loramyc® in oropharyngeal candidiasis in the USA and acyclovir Lauriad® in oral herpes), and a third based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells (doxorubicin Transdrug® in primary liver cancer). The company is also developing a new therapeutic entities program focused on the oncology and HIV markets.

This year, the company has established strategic alliances for commercializing Loramyc® in Europe and the USA.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma S.A.'s website ( http://www.bioalliancepharma.com ).

For more information, please click here

Contacts:


BioAlliance Pharma SA
Dominique Costantini
President and CEO
Tel.: +33 1 45 58 76 01

or
Nicolas Fellmann
CFO
Tel.: +33 1 45 58 71 00

or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Announcements

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

NanoScience: Giants of the Infinitesimal July 31st, 2014

Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE